What changed from existing technology?
This study shows that briefly changing a specific protein in breast cancer cells can make them less likely to change into different types of cells, which might help prevent cancer from coming back or spreading.
This is the first study to show that transient CB2R modulation can durably restrict breast cancer cell plasticity by stabilizing a luminal-like cell state.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
ticity by stabilizing a luminal-like cell state. Using patient-derived and murine tumor organoids, we demonstrate that brief, low-dose CB2R modulation reduce
Abstract ↗al approaches that induce durable lineage restriction remain limited. Here, we show that transient modulation of cannabinoid receptor 2 (CB2R) durably re
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests a potential therapeutic strategy for preventing breast cancer recurrence or metastasis by stabilizing tumor cell identity through transient CB2R modulation.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.